Expression of Cancer/Testis Antigens is Correlated with Improved Survival in Glioblastoma
Autor(a) principal: | |
---|---|
Data de Publicação: | 2013 |
Outros Autores: | , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNIFESP |
Texto Completo: | http://repositorio.unifesp.br/11600/45064 http://dx.doi.org/10.18632/oncotarget.950 |
Resumo: | Background: Glioblastoma (GBM) confers a dismal prognosis despite advances in current therapy. Cancer-testis antigens (CTA) comprise families of tumor-associated antigens that are immunogenic in different cancers. The aim of this study was to determine the expression profile of a large number of CTA genes in GBM.Methods: We selected, from 153 CTA genes, those genes potentially expressed in GBM. The expression pattern of 30 CTA was then evaluated by RT-PCR in a series of 48 GBM and 5 normal brain samples. The presence of CTCFL protein was also evaluated by immunohistochemical staining.Results: Among the genes with no expression in normal brain, ACTL8 (57%), OIP5 (54%), XAGE3 (44%) and CTCFL (15%) were frequently expressed in GBM, while over 85% of the tumors expressed at least 1 of these four CTA. Coexpression of two or more CTA occurred in 49% of cases. CTCFL protein expression was detected in 13% of the GBM and was negative in normal brain samples. GBM expressing 3-4 CTA was associated with significantly better overall survival (OS) rates (P = 0.017). By multivariate analysis, mRNA positivity for 3-4 CTA (P = 0.044), radiotherapy (P = 0.010) and chemotherapy (P = 0.001) were independent prognostic factors for OS.Conclusions: GBM frequently express ACTL8, OIP5, XAGE3 and CTCFL. A relatively high percentage of tumors expressed at least one of these four CTA, opening the perspective for their utility in antigen-specific immunotherapy. Furthermore, mRNA positivity for 3-4 CTA is an independent predictor of better OS for GBM patients. |
id |
UFSP_a67d3803d8bc0b159d8c9a5948113e19 |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br:11600/45064 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
Freitas, Marcelo Roberto Pereira [UNIFESP]Malheiros, Suzana Maria Fleury [UNIFESP]Stávale, João Norberto [UNIFESP]Biassi, Thais Priscila [UNIFESP]Zamuner, Fernando Tadeu [UNIFESP]Begnami, Maria Dirlei Ferreira de SouzaSoares, Fernando AugustoVettore, Andre Luiz [UNIFESP]Universidade Federal de São Paulo (UNIFESP)AC Camargo Canc Hosp2018-06-18T11:23:31Z2018-06-18T11:23:31Z2013-04-01Oncotarget. Albany: Impact Journals Llc, v. 4, n. 4, p. 636-646, 2013.1949-2553http://repositorio.unifesp.br/11600/45064http://dx.doi.org/10.18632/oncotarget.950WOS000318783800015.pdf10.18632/oncotarget.950WOS:000318783800015Background: Glioblastoma (GBM) confers a dismal prognosis despite advances in current therapy. Cancer-testis antigens (CTA) comprise families of tumor-associated antigens that are immunogenic in different cancers. The aim of this study was to determine the expression profile of a large number of CTA genes in GBM.Methods: We selected, from 153 CTA genes, those genes potentially expressed in GBM. The expression pattern of 30 CTA was then evaluated by RT-PCR in a series of 48 GBM and 5 normal brain samples. The presence of CTCFL protein was also evaluated by immunohistochemical staining.Results: Among the genes with no expression in normal brain, ACTL8 (57%), OIP5 (54%), XAGE3 (44%) and CTCFL (15%) were frequently expressed in GBM, while over 85% of the tumors expressed at least 1 of these four CTA. Coexpression of two or more CTA occurred in 49% of cases. CTCFL protein expression was detected in 13% of the GBM and was negative in normal brain samples. GBM expressing 3-4 CTA was associated with significantly better overall survival (OS) rates (P = 0.017). By multivariate analysis, mRNA positivity for 3-4 CTA (P = 0.044), radiotherapy (P = 0.010) and chemotherapy (P = 0.001) were independent prognostic factors for OS.Conclusions: GBM frequently express ACTL8, OIP5, XAGE3 and CTCFL. A relatively high percentage of tumors expressed at least one of these four CTA, opening the perspective for their utility in antigen-specific immunotherapy. Furthermore, mRNA positivity for 3-4 CTA is an independent predictor of better OS for GBM patients.Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)Univ Fed Sao Paulo, Lab Mol Canc Biol, Dept Sci Biol, Sao Paulo, BrazilUniv Fed Sao Paulo, Dept Neurol, Sao Paulo, BrazilUniv Fed Sao Paulo, Dept Pathol, Sao Paulo, BrazilAC Camargo Canc Hosp, Dept Pathol, Sao Paulo, BrazilUniv Fed Sao Paulo, Lab Mol Canc Biol, Dept Sci Biol, Sao Paulo, BrazilUniv Fed Sao Paulo, Dept Neurol, Sao Paulo, BrazilUniv Fed Sao Paulo, Dept Pathol, Sao Paulo, BrazilFAPESP: 2010/20218/2Web of Science636-646engImpact Journals LlcOncotargetBrain cancerGlioblastomaGBMCancer/Testis antigensCTA expressionExpression of Cancer/Testis Antigens is Correlated with Improved Survival in Glioblastomainfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP11600/450642021-09-29 12:11:15.825metadata only accessoai:repositorio.unifesp.br:11600/45064Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestopendoar:34652023-05-25T12:27:18.628915Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.en.fl_str_mv |
Expression of Cancer/Testis Antigens is Correlated with Improved Survival in Glioblastoma |
title |
Expression of Cancer/Testis Antigens is Correlated with Improved Survival in Glioblastoma |
spellingShingle |
Expression of Cancer/Testis Antigens is Correlated with Improved Survival in Glioblastoma Freitas, Marcelo Roberto Pereira [UNIFESP] Brain cancer Glioblastoma GBM Cancer/Testis antigens CTA expression |
title_short |
Expression of Cancer/Testis Antigens is Correlated with Improved Survival in Glioblastoma |
title_full |
Expression of Cancer/Testis Antigens is Correlated with Improved Survival in Glioblastoma |
title_fullStr |
Expression of Cancer/Testis Antigens is Correlated with Improved Survival in Glioblastoma |
title_full_unstemmed |
Expression of Cancer/Testis Antigens is Correlated with Improved Survival in Glioblastoma |
title_sort |
Expression of Cancer/Testis Antigens is Correlated with Improved Survival in Glioblastoma |
author |
Freitas, Marcelo Roberto Pereira [UNIFESP] |
author_facet |
Freitas, Marcelo Roberto Pereira [UNIFESP] Malheiros, Suzana Maria Fleury [UNIFESP] Stávale, João Norberto [UNIFESP] Biassi, Thais Priscila [UNIFESP] Zamuner, Fernando Tadeu [UNIFESP] Begnami, Maria Dirlei Ferreira de Souza Soares, Fernando Augusto Vettore, Andre Luiz [UNIFESP] |
author_role |
author |
author2 |
Malheiros, Suzana Maria Fleury [UNIFESP] Stávale, João Norberto [UNIFESP] Biassi, Thais Priscila [UNIFESP] Zamuner, Fernando Tadeu [UNIFESP] Begnami, Maria Dirlei Ferreira de Souza Soares, Fernando Augusto Vettore, Andre Luiz [UNIFESP] |
author2_role |
author author author author author author author |
dc.contributor.institution.none.fl_str_mv |
Universidade Federal de São Paulo (UNIFESP) AC Camargo Canc Hosp |
dc.contributor.author.fl_str_mv |
Freitas, Marcelo Roberto Pereira [UNIFESP] Malheiros, Suzana Maria Fleury [UNIFESP] Stávale, João Norberto [UNIFESP] Biassi, Thais Priscila [UNIFESP] Zamuner, Fernando Tadeu [UNIFESP] Begnami, Maria Dirlei Ferreira de Souza Soares, Fernando Augusto Vettore, Andre Luiz [UNIFESP] |
dc.subject.eng.fl_str_mv |
Brain cancer Glioblastoma GBM Cancer/Testis antigens CTA expression |
topic |
Brain cancer Glioblastoma GBM Cancer/Testis antigens CTA expression |
description |
Background: Glioblastoma (GBM) confers a dismal prognosis despite advances in current therapy. Cancer-testis antigens (CTA) comprise families of tumor-associated antigens that are immunogenic in different cancers. The aim of this study was to determine the expression profile of a large number of CTA genes in GBM.Methods: We selected, from 153 CTA genes, those genes potentially expressed in GBM. The expression pattern of 30 CTA was then evaluated by RT-PCR in a series of 48 GBM and 5 normal brain samples. The presence of CTCFL protein was also evaluated by immunohistochemical staining.Results: Among the genes with no expression in normal brain, ACTL8 (57%), OIP5 (54%), XAGE3 (44%) and CTCFL (15%) were frequently expressed in GBM, while over 85% of the tumors expressed at least 1 of these four CTA. Coexpression of two or more CTA occurred in 49% of cases. CTCFL protein expression was detected in 13% of the GBM and was negative in normal brain samples. GBM expressing 3-4 CTA was associated with significantly better overall survival (OS) rates (P = 0.017). By multivariate analysis, mRNA positivity for 3-4 CTA (P = 0.044), radiotherapy (P = 0.010) and chemotherapy (P = 0.001) were independent prognostic factors for OS.Conclusions: GBM frequently express ACTL8, OIP5, XAGE3 and CTCFL. A relatively high percentage of tumors expressed at least one of these four CTA, opening the perspective for their utility in antigen-specific immunotherapy. Furthermore, mRNA positivity for 3-4 CTA is an independent predictor of better OS for GBM patients. |
publishDate |
2013 |
dc.date.issued.fl_str_mv |
2013-04-01 |
dc.date.accessioned.fl_str_mv |
2018-06-18T11:23:31Z |
dc.date.available.fl_str_mv |
2018-06-18T11:23:31Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
Oncotarget. Albany: Impact Journals Llc, v. 4, n. 4, p. 636-646, 2013. |
dc.identifier.uri.fl_str_mv |
http://repositorio.unifesp.br/11600/45064 http://dx.doi.org/10.18632/oncotarget.950 |
dc.identifier.issn.none.fl_str_mv |
1949-2553 |
dc.identifier.file.none.fl_str_mv |
WOS000318783800015.pdf |
dc.identifier.doi.none.fl_str_mv |
10.18632/oncotarget.950 |
dc.identifier.wos.none.fl_str_mv |
WOS:000318783800015 |
identifier_str_mv |
Oncotarget. Albany: Impact Journals Llc, v. 4, n. 4, p. 636-646, 2013. 1949-2553 WOS000318783800015.pdf 10.18632/oncotarget.950 WOS:000318783800015 |
url |
http://repositorio.unifesp.br/11600/45064 http://dx.doi.org/10.18632/oncotarget.950 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.none.fl_str_mv |
Oncotarget |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
636-646 |
dc.publisher.none.fl_str_mv |
Impact Journals Llc |
publisher.none.fl_str_mv |
Impact Journals Llc |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
|
_version_ |
1783460292936597504 |